Portal hypertension (PH) is the main driver of cirrhosis decompensation, the main
determinant of death in patients with cirrhosis. PH results initially from increased intrahepatic …

Portal hypertension is most frequently associated with cirrhosis and is a major driver for
associated complications, such as variceal bleeding, ascites or hepatic encephalopathy. As …

Portal hypertension and bleeding from gastroesophageal varices is the major cause of
morbidity and mortality in patients with cirrhosis. Portal hypertension is initiated by increased …

Introduction: Counteracting splanchnic vasodilatation and increased portal-collateral blood
flow has been the mainstay for the treatment of portal hypertension (PH) over the past three …

Portal hypertension is one cause and a part of a dynamic process triggered by chronic liver
disease, mostly induced by alcohol or incorrect nutrition and less often by viral infections …

Non-selective beta blockers (NSBB) have been the mainstay of therapy for portal
hypertension for the past 25 years, ever since Lebrec et al. demonstrated in a randomized …

In patients with chronic liver disease, portal hypertension is driven by progressive fibrosis
and intrahepatic vasoconstriction. Interruption of the initiating and perpetuating etiology …

Portal hypertension (PH) is responsible for the most severe complications of cirrhosis and
leading cause of death and liver transplantation. The standard pharmacological treatment …

Abstract Background/Aim We investigated the effect of non-selective β-blockers (NSBB) in
real-world situations and whether low-dose NSBB is beneficial compared to maximally …

Background Liver cirrhosis is the fourth cause of death in adults in Western countries, with
complications of portal hypertension being responsible for most casualties. In order to …